Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Manuel Piechutta"'
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
Autor:
Manuel Piechutta, Anna Sophie Berghoff
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 3 (2019)
Externí odkaz:
https://doaj.org/article/e415066bd41546f9bfdbd5537ee1895e
Autor:
Martin Bendszus, Felix T. Kurz, Allen Alexander, Michael Platten, Frank Winkler, Michael O. Breckwoldt, Wolfgang Wick, Sabine Heiland, Matthia A. Karreman, Katrin Deumelandt, Philipp C. Münch, Kianush Karimian-Jazi, Manuel Piechutta, Manuel Fischer, Gergely Solecki, Mirco Friedrich, Kira Pfleiderer, Anna S. Berghoff
Publikováno v:
Theranostics
Rationale: Glioblastoma is the most frequent, primary brain tumor that is characterized by a highly immunosuppressive tumor microenvironment (TME). The TME plays a key role for tumor biology and the effectiveness of immunotherapies. Composition of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bda52493dfcf53f8f6ed707c30cb2b
https://doi.org/10.7150/thno.38659
https://doi.org/10.7150/thno.38659
Autor:
Julia M. Messmer, Manuel Piechutta, Varun Venkataramani, Chanté Mayer, Anna S. Berghoff, Daniel Hinze, Michael Hölzel, Iris Helfrich, Dirk Schadendorf, Wolfgang Wick, Matthia A. Karreman, Frank Winkler
Publikováno v:
Cancer Research. 82:2487-2487
Immune checkpoint therapy has demonstrated potential for the treatment of brain metastases, but the mechanisms of lymphocyte recruitment to brain tumors are poorly understood. To monitor T cell infiltration and brain tumor growth in vivo in real time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba1fbbdd8de0e6140587d2c767165dfc
https://doi.org/10.1158/1538-7445.am2022-2487
https://doi.org/10.1158/1538-7445.am2022-2487
Autor:
Wolfgang Wick, Manuel Piechutta, Matthia A. Karreman, K Gunkel, Manuel Feinauer, Anna S. Berghoff, Frank Winkler
Publikováno v:
Europe PubMed Central
BACKGROUND: Brain metastases (BM) are a devastating and frequent complication in patient with metastatic cancer. Survival is severely limited as the current treatment strategies have to conquer several obstacles in symptomatic BM including the hetero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::310a538d0cabe001bb60a07a09ce140c
https://doi.org/10.1093/neuonc/noy139.223
https://doi.org/10.1093/neuonc/noy139.223